An Irish analysis in the Bio ImPAcT Consortium reported low biosimilar adoption in Irish oncology despite biosimilars representing roughly half of oncology biologics. The authors argued that uneven uptake limits potential savings and patient access, contrasting Ireland’s lower penetration with consistently higher biosimilar use in peer markets. Separately, a cost-effectiveness evaluation in China suggested belantamab requires an approximate 98% price reduction versus the US list price to reach cost-effectiveness thresholds for relapsed or refractory multiple myeloma. Together, the pieces underline how reimbursement and pricing decisions continue to shape which oncology treatments patients can realistically access.
Get the Daily Brief